Clinical Trial Update: Open-Label, Dose-Finding Study Evaluating Safety and PK of FPA144 in Patients With Advanced Solid Tumors [Phase 1]

View source ↗

Summary

This Phase 1 open-label dose-finding study evaluated the safety and pharmacokinetics of FPA144 in patients with advanced solid tumors, including gastric cancer,…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Transitional Cell Carcinoma of the Bladder

Drugs mentioned

• FPA144 (FGFR2b-targeted monoclonal antibody)

Snippet

Sponsor: Five Prime Therapeutics, Inc. | Conditions: Advanced Solid Tumors, Gastric Cancer | Phase 1 | Status: COMPLETED | Results posted: 2020-03-11